Philip Wagenheim - 10 Jun 2026 Form 4 Insider Report for Immunome Inc. (IMNM)

Reporting relationship: Director
Issuer ticker: IMNM
Reported as of: 10 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 17:56:21 UTC
Prior SEC filing: 23 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Sandra Stoneman, Attorney-in-Fact

Key filing fact

Philip Wagenheim filed Form 4 for Immunome Inc. (IMNM) on 12 Jun 2026.

Key facts

This page summarizes Philip Wagenheim's Form 4 filing for Immunome Inc. (IMNM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 17:56.

Change

Previous filing in this sequence was filed on 23 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001405684 Primary reporting owner

WAGENHEIM PHILIP

Relationship: Director
Address: C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL
Signature: /s/ Sandra Stoneman, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMNM transaction Derivative

Director Stock Option (right to buy)

Award

Transaction value
Shares: +9,897
Change %
Price: $0.000000^*
Shares after: 9,897
Date: 10 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,897
Exercise price: $18.16
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests in four equal quarterly installments, commencing from June 10, 2026 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.